Research programme: p53 targeted cancer therapeutics - EleosAlternative Names: Antisense p53 therapeutics - Eleos
Latest Information Update: 18 Jul 2012
At a glance
- Originator Eleos
- Class Antisense elements
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 18 Jul 2012 No development reported - Preclinical for Cancer in USA (unspecified route)
- 12 Jul 2012 AVI Biopharma is now called Sarepta Therapeutics
- 31 Dec 2008 The collaboration with Eleos and AVI BioPharma is still active